RESULTS FOR : 'Immunotherapy'
Showing 1 to 8 of 8 results |    
Keyword Search
Show#
Show#
Results Category/Section
Monitoring the balance between immune repression and stimulation in cancer immunotherapy

Cancer is still one of the main causes of death worldwide, yet recent strides towards more effective treatments have been made in the form of new cancer immunotherapies.

Ex Vivoverus in Vivo - the challenge of generating meaningful results with traditional cell culture

While the use of human cell lines has become a permanent fixture in drug discovery and development, the lingering issue has been in their inconsistent results.

Synthetic lethality and anti cancer drug discovery

Classically-activated oncogene targets have been a mainstay of cancer drug discovery for the past 15 years, but the druggable targets in this category have been largely mined out.

Valuation in portfolio management.

Throughout the course of my career, I have been involved in a wide range of portfolio decisions and continue to be involved in them today. Over the years, it has been observed that despite cultural differences, pharma teams face similar problems.

The use of syngeneic models for the discovery of targets for combination therapy and predictive biomarkers of immunotherapy efficacy.

Optimal treatment for any disease is one that can cure or prevent spreading with minimal impact on the patient’s quality of life. In the case of cancer, therapeutic agents were initially designed to kill rapidly dividing cells.

CAR-T : Looking beyond the hype.

While CAR-Ts have already demonstrated convincing efficacy in a specific setting, the jury is still out on whether they are a ‘game-changer’ for oncology as a whole and can justify current valuations and investor interest.

Anti-infective immunotherapy for treating hospital acquired infections.

The frequency of nosocomial (acquired in healthcare facility) pneumonia has experienced a steady increase in recent years, and treatment of these infections has become more challenging and expensive due to the emergence of multi-drug resistant bacterial strains.

Immunotherapeutics: the coming of age of cancer immunotherapy as a treatment paradigm.

As the oncology drug development landscape has evolved, so too have the processes, methods and equipment used in the fight against cancer. Traditional treatments such as chemotherapy and radiation therapy are still very popular and remain effective methods of fighting the disease as a whole.